Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

Stopped early · Phase 1

Conditions studied: Lymphoma, Leukemia, Cancer

In brief

For primary objectives, we will determine the MTD and examine clinical responses and immune cell populations to determine an OBD, and describe the safety and tolerability of MEDI-507. For the secondary objectives we will look at the antitumor activity of MEDI 507, PK, serum concentrations, and immunogenicity of MEDI-507, as well as time courses of depletion and recovery of CD2 positive and total T-Cell populations.

Key facts

Study ID

NCT00105313

Run by

MedImmune LLC

People needed

80

Starts

2005-02-01

Last updated by the study team

2007-06-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• USC/Norris Cancer Center — Los Angeles, California, United States
• Yale Cancer Center — New Haven, Connecticut, United States
• Georgetown University Medical Center, Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia, United States
• H. Lee Moffitt Cancer Ctr & Research Institute Div of Hem/Onc — Tampa, Florida, United States
• University of Maryland School of Medicine, Greenebaum Cancer Center — Baltimore, Maryland, United States
• Tufts New England Medical Center — Boston, Massachusetts, United States
• Washington University — St Louis, Missouri, United States
• Nevada Cancer Institute — Las Vegas, Nevada, United States
• Wake Forest University Health Sciences — Winston-Salem, North Carolina, United States
• Kimmel Cancer Center, Thomas Jefferson University — Philadelphia, Pennsylvania, United States
• M.D. Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.